Intermediate Uveitis
Drug research and approvals for intermediate Uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 2 studies of intermediate Uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 2
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 2 recruiting on ClinicalTrials.gov ↗- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)NCT07861074 · Phase 2 · Merck Sharp & Dohme LLC · starts Nov 4, 2026
- A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active,…NCT07427628 · Phase 1 · Quan Dong Nguyen · starts Mar 18, 2026
Drug Pipeline
6 in phase 3, 4 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Voclosporin
- Phase 3 Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
- Methotrexate
- Phase 3 Dihydrofolate reductase inhibitor
- Mycophenolic acid
- Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Prednisone
- Phase 3 Glucocorticoid receptor agonist
- Fluocinolone acetonide
- Phase 3 Glucocorticoid receptor agonist
- Interferon beta
- Phase 3
- Sirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Dexamethasone
- Phase 2 Glucocorticoid receptor agonist
- Piclidenoson
- Phase 2 Adenosine A3 receptor agonist
- Tesidolumab
- Phase 2 Complement C5 binding agent
- Tocilizumab
- Phase 1 Interleukin-6 receptor alpha subunit inhibitor
How Its Trials Ended
31 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 56% met their primary endpoint, 0% missed it and 44% stopped early.
- Completed, result not reported1032%
- Met its primary endpoint929%
- Stopped: other or unclear413%
- Status unknown310%
- Ongoing26%
- Stopped: sponsor or business decision26%
- Stopped: safety13%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 3, 2026 | A phase 2b, randomized, double-masked, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with active noninfectious…MK-7240 (tulisokibart) / prednisone | Merck & Co. (MSD) | Pending |
| Jul 25, 2013 | A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate,…Gevokizumab | Servier | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 4, 2011 | SirolimusTreatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and… | Santen Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA